in

Dabrafenib, trametinib found more effective in pediatric glioma with BRAF V600

Dabrafenib, trametinib active in pediatric glioma with BRAF V600

Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a study published in the Sept. 21 issue of the New England Journal of Medicine.


Posted by Editor

JD Sports Sees Air Force Ones, Gazelle Sneakers Driving Profits Higher

JD Sports Sees Air Force Ones, Gazelle Sneakers Driving Profits Higher

Anita Goundrey

‘You have alzheimer’s…’ What it’s really like to hear those words